Immunosuppressants Market (By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others; By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases; By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies; By Route of Administration: Oral, Parenteral) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 190

Table Of Content:

CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
   1.1.1. Definition of Immunosuppressants
   1.1.2. Market Segmentation
   1.1.3. List of Abbreviations
1.2. Summary
   1.2.1. Market Snapshot
   1.2.2. Immunosuppressants Market By Drug Class
     1.2.2.1. Global Immunosuppressants Market Revenue and Growth Rate Comparison By Drug Class (2020-2027)
     1.2.2.2. Global Immunosuppressants Market Revenue Share By Drug Class in 2019
     1.2.2.3. Corticosteroids
     1.2.2.4. Monoclonal Antibodies (mAbs)
     1.2.2.5. Calcineurin Inhibitors
     1.2.2.6. mTOR Inhibitors
     1.2.2.7. Anti-Proliferative Agents
     1.2.2.8. Others
   1.2.3. Immunosuppressants Market By Indication
     1.2.3.1. Global Immunosuppressants Market Revenue and Growth Rate Comparison By Indication (2020-2027)
       1.2.3.1.1. Organ Transplantation
       1.2.3.1.2. Autoimmune Disorders
       1.2.3.1.3. Non-Autoimmune Inflammatory Diseases
   1.2.4. Immunosuppressants Market By Distribution Channel
     1.2.4.1. Global Immunosuppressants Market Revenue and Growth Rate Comparison By Distribution Channel (2020-2027)
     1.2.4.2. Hospital pharmacies
     1.2.4.3. Retail pharmacies
     1.2.4.4. Online pharmacies
   1.2.5. Immunosuppressants Market By Route of Administration
     1.2.5.1. Global Immunosuppressants Market Revenue and Growth Rate Comparison By Route of Administration (2020-2027)
     1.2.5.2. Oral
     1.2.5.3. Parenteral
   1.2.6. Immunosuppressants Market By Geography
     1.2.6.1. Global Immunosuppressants Market Revenue and Growth Rate Comparison by Geography (2020-2027)
     1.2.6.2. North America Immunosuppressants Market Revenue and Growth Rate(2020-2027)
     1.2.6.3. Europe Immunosuppressants Market Revenue and Growth Rate(2020-2027)
     1.2.6.4. Asia-Pacific Immunosuppressants Market Revenue and Growth Rate(2020-2027)
     1.2.6.5. Latin America Immunosuppressants Market Revenue and Growth Rate(2020-2027)
     1.2.6.6. Middle East and Africa (MEA) Immunosuppressants Market Revenue and Growth Rate(2020-2027)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
   2.4.1. Bargaining Power of Suppliers
   2.4.2. Bargaining Power of Buyers
   2.4.3. Threat of Substitute
   2.4.4. Threat of New Entrants
   2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
   2.6.1. Raw Material and Suppliers
   2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2019
   2.8.1. Player Positioning Analysis
   2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Immunosuppressants Major Manufacturers in 2019
3.2. Manufacturing Plants Distribution of Global Immunosuppressants Major Manufacturers in 2019
3.3. R&D Status and Technology Source of Global Immunosuppressants Major Manufacturers in 2019
3.4. Raw Materials Sources Analysis of Global Immunosuppressants Major Manufacturers in 2019

CHAPTER 4. IMMUNOSUPPRESSANTS MARKET BY DRUG CLASS
4.1. Global Immunosuppressants Revenue By Drug Class
4.2. Corticosteroids
   4.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.3. Monoclonal Antibodies (mAbs)
   4.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.4. Calcineurin Inhibitors
   4.4.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.4.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.5. mTOR Inhibitors
   4.5.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.5.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.6. Anti-Proliferative Agents
   4.6.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.6.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
4.7. Ohers
   4.7.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   4.7.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)

CHAPTER 5. IMMUNOSUPPRESSANTS MARKET BY INDICATION
5.1. Global Immunosuppressants Revenue By Indication
5.2. Organ Transplantation
   5.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   5.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
5.3. Autoimmune Disorders
   5.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   5.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
5.4. Non-Autoimmune Inflammatory Diseases
   5.4.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   5.4.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)

CHAPTER 6. IMMUNOSUPPRESSANTS MARKET BY DISTRIBUTION CHANNEL
6.1. Global Immunosuppressants Revenue By Distribution Channel
6.2. Hospital pharmacies
   6.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   6.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
6.3. Retail pharmacies
   6.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   6.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
6.4. Online pharmacies
   6.4.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   6.4.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)

CHAPTER 7. IMMUNOSUPPRESSANTS MARKET BY ROUTE OF ADMINISTRATION
7.1. Global Immunosuppressants Revenue By Route of Administration
7.2. Oral
   7.2.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   7.2.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)
7.3. Parenteral
   7.3.1. Market Revenue and Growth Rate, 2020 - 2027 ($Million)
   7.3.2. Market Revenue and Forecast, By Region, 2020 - 2027 ($Million)

CHAPTER 8. NORTH AMERICA IMMUNOSUPPRESSANTS MARKET BY COUNTRY
8.1. North America Immunosuppressants Market Revenue and Growth Rate, 2020 - 2027 ($Million)
8.2. North America Immunosuppressants Market Revenue Share Comparison, 2020 & 2027 (%)
8.3. U.S.
   8.3.1. U.S. Immunosuppressants Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   8.3.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   8.3.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   8.3.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
8.4. Canada
   8.4.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   8.4.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   8.4.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   8.4.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)

CHAPTER 9. EUROPE IMMUNOSUPPRESSANTS MARKET BY COUNTRY
9.1. Europe Immunosuppressants Market Revenue and Growth Rate, 2020 - 2027 ($Million)
9.2. Europe Immunosuppressants Market Revenue Share Comparison, 2020 & 2027 (%)
9.3. UK
   9.3.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   9.3.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   9.3.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   9.3.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
9.4. Germany
   9.4.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   9.4.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   9.4.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   9.4.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
9.5. France
   9.5.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   9.5.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   9.5.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   9.5.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
9.6. Spain
   9.6.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   9.6.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   9.6.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   9.6.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
9.7. Rest of Europe
   9.7.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   9.7.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   9.7.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   9.7.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)

CHAPTER 10. ASIA-PACIFIC IMMUNOSUPPRESSANTS MARKET BY COUNTRY
10.1. Asia-Pacific Immunosuppressants Market Revenue and Growth Rate, 2020 - 2027 ($Million)
10.2. Asia-Pacific Immunosuppressants Market Revenue Share Comparison, 2020 & 2027 (%)
10.3. China
   10.3.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.3.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.3.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.3.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
10.4. Japan
   10.4.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.4.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.4.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.4.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
10.5. India
   10.5.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.5.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.5.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.5.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
10.6. Australia
   10.6.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.6.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.6.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.6.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
10.7. South Korea
   10.7.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.7.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.7.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.7.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
10.8. Rest of Asia-Pacific
   10.8.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   10.8.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   10.8.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   10.8.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)

CHAPTER 11. LATIN AMERICA IMMUNOSUPPRESSANTS MARKET BY COUNTRY
11.1. Latin America Immunosuppressants Market Revenue and Growth Rate, 2020 - 2027 ($Million)
11.2. Latin America Immunosuppressants Market Revenue Share Comparison, 2020 & 2027 (%)
11.3. Brazil
   11.3.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   11.3.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   11.3.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   11.3.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
11.4. Mexico
   11.4.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   11.4.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   11.4.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   11.4.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
11.5. Rest of Latin America
   11.5.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   11.5.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   11.5.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   11.5.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)

CHAPTER 12. MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS MARKET BY COUNTRY
12.1. Middle East & Africa Immunosuppressants Market Revenue and Growth Rate, 2020 - 2027 ($Million)
12.2. Middle East & Africa Immunosuppressants Market Revenue Share Comparison, 2020 & 2027 (%)
12.3. GCC
   12.3.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   12.3.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   12.3.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   12.3.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
12.4. South Africa
   12.4.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   12.4.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   12.4.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   12.4.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)
12.5. Rest of Middle East & Africa
   12.5.1. Market Revenue and Forecast By Drug Class, 2020 - 2027 ($Million)
   12.5.2. Market Revenue and Forecast By Indication, 2020 - 2027 ($Million)
   12.5.3. Market Revenue and Forecast By Distribution Channel, 2020 - 2027 ($Million)
   12.5.4. Market Revenue and Forecast By Route of Administration, 2020 - 2027 ($Million)

CHAPTER 13. COMPANY PROFILE
13.1. Novartis AG
   13.1.1. Company Snapshot
   13.1.2. Overview
   13.1.3. Financial Overview
   13.1.4. Type Portfolio
   13.1.5. Key Developments
   13.1.6. Strategies
13.2. Bristol Myers Squibb
   13.2.1. Company Snapshot
   13.2.2. Overview
   13.2.3. Financial Overview
   13.2.4. Type Portfolio
   13.2.5. Key Developments
   13.2.6. Strategies
13.3. Zydus
   13.3.1. Company Snapshot
   13.3.2. Overview
   13.3.3. Financial Overview
   13.3.4. Type Portfolio
   13.3.5. Key Developments
   13.3.6. Strategies
13.4. GlaxoSmithKline Plc.
   13.4.1. Company Snapshot
   13.4.2. Overview
   13.4.3. Financial Overview
   13.4.4. Type Portfolio
   13.4.5. Key Developments
   13.4.6. Strategies
13.5. Astellas Pharma, Inc.
   13.5.1. Company Snapshot
   13.5.2. Overview
   13.5.3. Financial Overview
   13.5.4. Type Portfolio
   13.5.5. Key Developments
   13.5.6. Strategies
13.6. Johnson & Johnson
   13.6.1. Company Snapshot
   13.6.2. Overview
   13.6.3. Financial Overview
   13.6.4. Type Portfolio
   13.6.5. Key Developments
   13.6.6. Strategies
13.7. F. Hoffmann La Roche Ltd.
   13.7.1. Company Snapshot
   13.7.2. Overview
   13.7.3. Financial Overview
   13.7.4. Type Portfolio
   13.7.5. Key Developments
   13.7.6. Strategies
13.8. Mylan Laboratories Inc.
   13.8.1. Company Snapshot
   13.8.2. Overview
   13.8.3. Financial Overview
   13.8.4. Type Portfolio
   13.8.5. Key Developments
   13.8.6. Strategies
13.9. Pfizer, Inc.
   13.9.1. Company Snapshot
   13.9.2. Overview
   13.9.3. Financial Overview
   13.9.4. Type Portfolio
   13.9.5. Key Developments
   13.9.6. Strategies
13.10. Intas Pharmaceuticals Ltd.
   13.10.1. Company Snapshot
   13.10.2. Overview
   13.10.3. Financial Overview
   13.10.4. Type Portfolio
   13.10.5. Key Developments
   13.10.6. Strategies
13.11. Others
   13.11.1. Company Snapshot
   13.11.2. Overview
   13.11.3. Financial Overview
   13.11.4. Type Portfolio
   13.11.5. Key Developments
   13.11.6. Strategies

CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
   14.1.1. Initial Data Search
   14.1.2. Secondary Research
   14.1.3. Primary Research
14.2. Assumptions and Scope


Cart Summary